Contribution of intrinsic fluorescence to the design of a new 3D-printed implant for releasing SDABS

Alexandre Nicolas (1, 2) , Alice Dejoux (2) , Cécile Poirier (2) , Nicolas Aubrey (3) , Jean-Manuel Péan (2) , Florence Velge-Roussel (1)

1 FRAME - GICC EA 7501, FRAME (Fc récepteur, anticorps et micro-environnement)
2 Technologie Servier
3 UMR ISP - Infectiologie et Santé Publique

Single-domain antibodies (sdAbs) offer great features such as increased stability but are hampered by a limited serum half-life. Many strategies have been developed to improve the sdAb half-life, such as protein engineering and controlled release systems (CRS). In our study, we designed a new product that combined a hydrogel with a 3D-printed implant. The results demonstrate the implant's ability to sustain sdAb release up to 13 days through a reduced initial burst release followed by a continuous release. Furthermore, formulation screening helped to identify the best sdAb formulation conditions and improved our understanding of our CRS. Through the screening step, we gained knowledge about the influence of the choice of polymer and about potential interactions between the sdAb and the polymer. To conclude, this feasibility study confirmed the ability of our CRS to extend sdAb release and established the fundamental role of formulation screening for maximizing knowledge about our CRS.

Mots clés: protein formulation(s); nanobody/V H H; scFv; bispecific antibody; controlled release; intrinsic fluorescence; thermo-responsive polymers; implant; 3D printing

Domaines: Immunothérapie; Immunité innée; Interactions cellulaires [q-bio.CB]; Biologie structurale [q-bio.BM]

Alexandre Nicolas, Alice Dejoux, Cécile Poirier, Nicolas Aubrey, Jean-Manuel Péan, et al.. Contribution of intrinsic fluorescence to the design of a new 3D-printed implant for releasing SDABS. Pharmaceutics, 2020, 12, 20 p. ⟨10.3390/pharmaceutics12100921⟩. ⟨hal-02964412⟩